Objective To explore the predictive value of spleen?liver volume ratio( SLVR) on the prog?nosis of partial hepatectomy in patients with hepatocellular carcinoma. Methods Clinical data of 86 cases of hepatocellular carcinoma underwent hepatectomy who were treated in the Traditional Chinese Medicine Hospital of Guangzhou from January 2009 to December 2014 were analyzed retrospectively. According to the preoperative spleen?liver volume ratio,these patients were divided into 2 groups:those with SLVR<0. 8 as low SLVR group with 44 cases, and SLVR ≥0. 8 as high SLVR group with 42 cases. Patients were followed?up until June 2015. Cox ratio risk pattern analysis was used for the recurrent correlative factors. Results The 1,3,5 year sur?vival rates of low SLVR group were 95. 5%, 88. 6%, 81. 8%, of the high SLVR group were 73. 8%, 47. 6%, 40. 5%,the differences between two group were statistically significant (χ2 = = 10. 223, 16. 098, 18. 010, P<0. 05) . Univariate analysis showed that,the maximum diameter of the tumor>5 cm,the number of tumor>3,por?tal vein or hepatic vein tumor thrombus,preoperative AFP?L3%≥10%,the rate of Invasion of blood vessels and the percentage of positive margins of high SLVR group all significantly lower than that of low SLVR group (25. 0%(11/44) vs. 59. 5%(25/42),22. 7%(10/44) vs. 54. 8%(23/42),9. 1%(4/44) vs. 26. 2%(11/42),38. 6%(17/44) vs. 78. 6%(33/42),18. 2%(8/44) vs. 38. 1%(16/42),2. 3%(1/44) vs. 14. 3%(6/42);χ2=20. 645,16. 180,24. 728,4. 819,18. 402,20. 105;P<0. 05) . Cox regression analysis revealed that di?ameter of the tumor>5 cm,SLVR ≥0. 8,AFP?L3≥10%,and portal vein or hepatic vein tumor thrombus were independent predictors of poor disease?free survival after hepatectomy for hepatocellular carcinoma( Or=6. 141, 3. 753,6. 968,7. 763;P<0. 05). Conclusion Preoperative SLVR ≥0. 8 is an independent adverse predictor of poor disease?free survival,can preliminarily predict the prognosis of patients with hepatocellular carcinoma.

Objective To investigate the effect of ampelopsin on apoptosis induction and cell growth inhibition in Human Colon cancer SW480 cells in vitro.Methods Treated with ampelopsin at several concentrations, MTT and flow cytometry was used to detect the inhibition rate and apoptotic rate of SW480 cells.Western-blot was used to investigate expression of Bcl-2 family pro-tein.Results Significant difference of cell growth inhibition rate was observed among all groups after treated with ampelopsin ( p<0.05).Cell growth inhibition rate in the low -dosage group was significantly high than that in median and high -dosage group (p<0.05), while no marked difference was observed between the median and high groups (p>0.05).The similar results were observed in the experiment on apoptosis induction.Level of Bcl-xL was significantly up-regulated.Level of Bax, Bid, Caspase-3, p-Ca-pase-9 and Caspase-9 was significantly down-regulated after treatment of ampelopsin.Conclusion Ampelopsin can inhibit cell growth and induce apoptosis of SW480.Bcl-2 family protein might be involved in the progress.

Objective To compare and analyze the short-term efficacy of modified intermediate laparoscopic right hemicolectomy (LRHC) and traditional intermediate laparoscopic right hemicolectomy (LRHC) in patients with colon cancer.Methods Eighty-four patients with colon cancer treated by laparoscopic right hemicolectomy (LRHC) from March 2014 to March 2018 in the General Surgery department of Guangzhou Hospital of Traditional Chinese Medicine were randomly divided into two groups.The control group was treated with traditional intermediate approach,while the improved group was treated with improved intermediate approach centering on the anterior pancreatic head region,with 42 cases in each group.The two groups of operations and related complications were statistically analyzed and compared.Results Compared to the control group,the improved group had less estimated mean blood loss ((39.5± 11.6) ml vs.(86.3± 13.7) ml,t =11.124,P＜0.05),shorter operative time((104.5±20.5) min vs.(139.3±25.9) min,t =6.094,P＜0.05) and lower intraoperative vascular damage rate (7.1％ (3/42) vs.23.8％ (10/42),x2=7.406,P＜0.05).There were no significant differences in the number of conversion to laparotomy,number of harvested lymph node,postoperative complications,hospital stay and quality of postoperative specimens between the two groups (P＞ 0.05).Conclusion Modified intermediate approach LRHC for colon cancer patients not only reduces the amount of bleeding and operation time,but also significantly reduces the rate of intraoperative vascular injury.

Objective: To analyze the clinical characteristics of cases of novel coronavirus pneumonia and a preliminary study to explore the relationship between different clinical classification and liver damage. Methods: Consecutively confirmed novel coronavirus infection cases admitted to seven designated hospitals during January 23, 2020 to February 8, 2020 were included. Clinical classification (mild, moderate, severe, and critical) was carried out according to the diagnosis and treatment program of novel coronavirus pneumonia (Trial Fifth Edition) issued by the National Health Commission. The research data were analyzed using SPSS19.0 statistical software. Quantitative data were expressed as median (interquartile range), and qualitative data were expressed as frequency and rate. Results: 32 confirmed cases that met the inclusion criteria were included. 28 cases were of mild or moderate type (87.50%), and four cases (12.50%) of severe or critical type. Four cases (12.5%) were combined with one underlying disease (bronchial asthma, coronary heart disease, malignant tumor, chronic kidney disease), and one case (3.13%) was simultaneously combined with high blood pressure and malignant tumor. The results of laboratory examination showed that the alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB), and total bilirubin (TBil) for entire cohort were 26.98 (16.88 ~ 46.09) U/L and 24.75 (18.71 ~ 31.79) U/L, 39.00 (36.20 ~ 44.20) g/L and 16.40 (11.34- ~ 21.15) mmol/L, respectively. ALT, AST, ALB and TBil of the mild or moderate subgroups were 22.75 (16.31- ~ 37.25) U/L, 23.63 (18.71 ~ 26.50) U/L, 39.70 (36.50 ~ 46.10) g/L, and 15.95 (11.34 ~ 20.83) mmol/L, respectively. ALT, AST, ALB and TBil of the severe or critical subgroups were 60.25 (40.88 ~ 68.90) U/L, 37.00 (20.88 ~ 64.45) U/L, 35.75 (28.68 ~ 42.00) g/L, and 20.50 (11.28 ~ 25.00) mmol/L, respectively. Conclusion The results of this multicenter retrospective study suggests that novel coronavirus pneumonia combined with liver damage is more likely to be caused by adverse drug reactions and systemic inflammation in severe patients receiving medical treatment. Therefore, liver function monitoring and evaluation should be strengthened during the treatment of such patients.